Plus TherapeuticsPSTV
PSTV
About: Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Employees: 21
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
13% more funds holding
Funds holding: 16 [Q1] → 18 (+2) [Q2]
2.56% less ownership
Funds ownership: 3.3% [Q1] → 0.74% (-2.56%) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
64% less capital invested
Capital invested by funds: $369K [Q1] → $132K (-$237K) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
518%
upside
Avg. target
$8.88
1,730%
upside
High target
$21
4,126%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Maxim Group Jason McCarthy | 518%upside $3 | Buy Maintained | 18 Aug 2025 |
HC Wainwright & Co. Sean Lee | 518%upside $3 | Buy Maintained | 27 Jun 2025 |
D. Boral Capital Jason Kolbert | 1,755%upside $9 | Hold Maintained | 25 Jun 2025 |
Ascendiant Capital Edward Woo | 4,126%upside $21 | Buy Maintained | 5 Jun 2025 |
Financial journalist opinion
Based on 6 articles about PSTV published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety profile HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces positive data from the ReSPECT-LM Phase 1 single dose escalation trial presented at the podium at the SNO/ASCO CNS Metastases Conference in Baltimore, MD. The data demonstrated treatment of leptomeningeal metastases (LM) with REYOBIQ is feasible, has a manageable safety profile, and shows a promising efficacy signal.
Neutral
GlobeNewsWire
1 week ago
Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders' equity of $3 million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”), as of June 30, 2025. The Equity Rule requires listed companies to maintain a minimum of $2.5 million in stockholders' equity.
Negative
Zacks Investment Research
1 week ago
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.71 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. “The second quarter of 2025 marked steady execution and progress on our key strategic initiatives: clinical development of our radiotherapeutic and the advancement of our diagnostic platform technologies toward commercialization,” said Marc H.
Neutral
GlobeNewsWire
1 week ago
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations
Neutral
GlobeNewsWire
3 weeks ago
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden regional availability over the next 12 months HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that its wholly-owned subsidiary, CNSide Diagnostics, LLC (“CNSide”) will make CNSide cerebrospinal fluid (CSF) assay platform and testing services commercially available in Texas in August 2025. Initial commercial focus will be on National Cancer Institute (NCI) Designated Cancer Centers, which treat the highest number of patients at risk for leptomeningeal metastases (LM) and previously used CNSide.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT
Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development program Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development program
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal Metastases” HOUSTON, July 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the oral presentation of its ReSPECT-LM clinical trial results and a sponsored educational symposium, at the upcoming SNO/ASCO CNS Metastases Conference on August 14-16, 2025, at the Baltimore Waterfront Marriott Hotel in Baltimore, MD. “Previously presented data from ReSPECT-LM was highly encouraging in both the safety profile and response signal in patients with leptomeningeal metastases or LM,” said Michael Rosol, Ph.D.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Substantial clinical need expected to facilitate rapid overall trial enrollment Substantial clinical need expected to facilitate rapid overall trial enrollment
Charts implemented using Lightweight Charts™